Welcome to our dedicated page for United Health Products SEC filings (Ticker: UEEC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on United Health Products's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into United Health Products's regulatory disclosures and financial reporting.
United Health Products, Inc. is updating its S-1 resale registration to incorporate its June 30, 2026 quarterly report, covering up to 25,669,288 shares of common stock for resale by a selling security holder. The company reported no revenue and a six-month net loss of $599,982, improving from a $1,854,316 loss a year earlier. Cash was $24,495 with total assets of $247,985 and a stockholders’ deficit of $4,442,816, and management states there is substantial doubt about its ability to continue as a going concern.
Current liabilities of $4,188,234 and a working capital deficit of $4,123,570 are funded mainly through convertible notes, related-party debt, and equity facilities, including an Any Market Purchase Agreement with Alumni Capital for up to $4,000,000 of stock purchases. The company continues to pursue FDA Class III Premarket Approval for its CelluSTAT hemostatic gauze and is working with NAMSA as proposed Sponsor for a new IDE clinical study while addressing an FDA Warning Letter and related CAPA and GCP audit requirements. Disclosure controls and procedures were assessed as not effective, and common shares outstanding were 262,685,588 as of August 14, 2026.
United Health Products, Inc. develops and manufactures CelluSTAT, a patented hemostatic gauze, and remains in a pre-revenue stage while pursuing U.S. Class III surgical market approval. For the six months ended June 30, 2026, it reported a net loss of $599,982, improved from $1,854,316 a year earlier, on operating expenses of $432,431.
Total assets were $247,985 and total liabilities $4,690,801, resulting in stockholders’ deficit of $4,442,816. Cash was $24,495 with a working capital deficit of $4,123,570, and the company disclosed substantial doubt about its ability to continue as a going concern.
The company continues to address an FDA Warning Letter tied to its 2018–2019 clinical study, with corrective and preventive actions, a GCP audit, and a plan for NAMSA to act as sponsor of a new IDE study whose data UHP may reference in a future PMA application. Liquidity support includes a convertible note and an Any Market Purchase Agreement with Alumni Capital for up to $4,000,000 in potential equity financing.
United Health Products, Inc. entered into a collaboration with MedTech contract research organization NAMSA, which will act as Sponsor of a new clinical study of UHP’s CelluSTAT Hemostatic Gauze. NAMSA will first seek an Investigational Device Exemption (IDE) to organize and conduct a study of UHP’s neutralized cellulose hemostat technology. Upon completion, UHP will hold an exclusive right of reference to all study data for use in a revised Premarket Approval (PMA) application. This approach permits the study to proceed, subject to IDE approval, while UHP continues working with the FDA to resolve an outstanding Warning Letter. NAMSA focuses entirely on medical device and in vitro diagnostic technologies and has experience with clinical trial management for Class III hemostatic agents and with the FDA Center for Devices and Radiological Health.
United Health Products, Inc. files a prospectus supplement to register 25,669,288 shares of common stock for resale by a selling security holder under its effective Form S-1. The supplement incorporates the Company’s Form 10-Q for the quarter ended March 31, 2026.
The supplement notes the Company’s OTCQB last quoted price of $0.054 per share as of May 21, 2026, and states shares issued and outstanding were 260,385,588 as of May 15, 2026. The 10-Q discloses a going concern warning, negative working capital, deferred offering costs of $169,582, and derivative liabilities of $118,844 as of March 31, 2026.
United Health Products, Inc. reported another pre-revenue quarter, posting a Q1 2026 net loss of $315,842, a sharp improvement from $1,531,659 a year earlier mainly due to much lower stock-based compensation and reduced R&D and consulting spend.
The company ended the quarter with only $1,029 in cash, a working capital deficit of $4,143,918, total assets of $248,825 and stockholders’ deficit of $4,192,293, and auditors highlight substantial doubt about its ability to continue as a going concern.
UHP remains focused on securing FDA Class III Premarket Approval for its CelluSTAT hemostatic gauze, but is operating under an FDA Warning Letter related to its 2018–2019 clinical study, must complete a GCP audit by late July 2026, and may rely on a prospective corporate partner to serve as sponsor of a new pivotal IDE study. To fund operations it is using highly dilutive instruments including convertible notes and an Any Market Purchase Agreement with Alumni Capital of up to $4,000,000, alongside 40.3 million unvested RSUs and 3.9 million warrants outstanding.
United Health Products, Inc. registers 25,669,288 shares of common stock for resale by Alumni Capital LP pursuant to agreements the company entered into on December 16, 2025. The registered shares comprise (i) 15,000,000 shares issuable under an Any Market Purchase Agreement (AMPA), (ii) 3,484,321 shares issuable upon exercise of a five‑year Commitment Warrant at $0.07462 per share, and (iii) 7,184,967 shares issuable upon conversion of a senior convertible note with an initial conversion price of $0.06039 per share. Alumni may sell the shares on the OTCQB (ticker UEEC) or otherwise; the company will not receive proceeds from Alumni’s resale activity, although it may receive proceeds if it elects to sell shares to Alumni under the AMPA or if the Commitment Warrant is exercised for cash. The prospectus discloses that the company had 258,690,253 shares outstanding prior to this offering and presents an assumed post‑issuance figure of 284,359,541 shares if all referenced issuances occur.
United Health Products, Inc. files a post-effective amendment to its Form S-1 registering 25,669,288 shares of common stock for resale by Alumni Capital LP. The registration includes (i) up to 15,000,000 shares the company may sell to Alumni under an Any Market Purchase Agreement, (ii) 3,484,321 shares issuable on a Commitment Warrant, and (iii) 7,184,967 shares issuable upon conversion of a $289,267 senior convertible note.
The amendment updates the S-1 to incorporate the company’s Form 10-K for the year ended December 31, 2025. The selling security holder will receive proceeds from any resale; the company may receive proceeds only from shares it elects to sell under the AMPA and from cash exercises of the Commitment Warrant. The prospectus discloses material FDA interactions on its Class III PMA pathway, identified internal-control weaknesses, a going-concern audit qualification, and working capital constraints.
United Health Products, Inc. reports another development-stage year focused on its CelluSTAT hemostatic gauze, with no revenue and a net loss of $2,669,348 for 2025, compared with a $2,001,733 loss in 2024. Operating expenses rose to $2,255,474, driven largely by higher stock-based compensation.
The company is seeking FDA Premarket Approval for Class III surgical use of CelluSTAT and is responding to an FDA Warning Letter tied to its 2018–2019 clinical study, including corrective actions and an external GCP audit. As of December 31, 2025, it had cash of $65,249, a working capital deficit of $3,837,757, and its auditor expressed substantial doubt about its ability to continue as a going concern.
To fund operations, UHP relied on equity-linked financing, including a $289,267 senior convertible note from Alumni Capital with $250,000 proceeds and an Any Market Purchase Agreement allowing sales of up to $4,000,000 of common stock through 2027. Management continues to explore strategic options such as partnerships, licensing, or a sale while pausing most commercial activity to focus on regulatory approvals.
United Health Products, Inc. notified the SEC that it could not file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 on time due to an extended auditors' final review caused by delayed debt confirmation responses from certain investors; the company expects to file within the fifteen-calendar day extension period.
The company reports total operating expenses of $2,438,765 for 2025 versus $2,007,572 in 2024, driven largely by a $1,270,772 increase in stock-based compensation (including vesting of 4,725,000 RSUs recorded as $1,120,125) and cites other income (expense) of $(442,342) for 2025 versus $5,839 in 2024. Net loss was $2,881,107 for 2025 versus $2,001,733 for 2024.